Show simple item record

dc.contributor.authorBibby, B
dc.contributor.authorThiruthaneeswaran, N
dc.contributor.authorYang, Lingjian
dc.contributor.authorMcArt, D
dc.contributor.authorO'Reilly, P
dc.contributor.authorRoberts, D
dc.contributor.authorChoudhury, Ananya
dc.contributor.authorWest, Catharine M L
dc.date.accessioned2018-08-27T16:10:25Z
dc.date.available2018-08-27T16:10:25Z
dc.date.issued2018
dc.identifier.citationRepurposing of FDA-approved drugs as novel radiosensitisers in hypoxic prostate cancer. 2018, 127: S195-S195 Radiother Oncolen
dc.identifier.urihttp://hdl.handle.net/10541/621210
dc.language.isoenen
dc.titleRepurposing of FDA-approved drugs as novel radiosensitisers in hypoxic prostate cancer.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity of Manchester, Division of Cancer Sciences, Manchesteren
dc.identifier.journalRadiotherapy and Oncologyen
refterms.dateFOA2018-12-17T15:35:14Z


Files in this item

Thumbnail
Name:
PIIS0167814018306923.pdf
Size:
556.8Kb
Format:
PDF
Description:
Full text, Open Access article

This item appears in the following Collection(s)

Show simple item record